Evidence map›Paper›PMID 40075580›Full record

ReviewCancers2025

Personalization of Cancer Treatment: Exploring the Role of Chronotherapy in Immune Checkpoint Inhibitor Efficacy.

Rosalyn M Fey, Avery Billo, Terri Clister, Khanh L Doan, Elizabeth G Berry, Deanne C Tibbitts, Rajan P Kulkarni

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Observational
  5. Review
  6. Hepatocellular Carcinoma Around the Clock.Current oncology (Toronto, Ont.) · 2026
    Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rosalyn M FeyDepartment of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0000-0002-3202-1012
Avery BilloDepartment of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA.
Terri ClisterDepartment of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0009-0000-8104-2242
Khanh L DoanDepartment of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0009-0006-1250-6035
Elizabeth G BerryDepartment of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0000-0002-7574-6718
Deanne C TibbittsDivision of Oncological Sciences, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0000-0001-6186-8338
Rajan P KulkarniDepartment of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0000-0002-2191-4085

Funding

Scholars in Women's Health Research Across the LifespanK12HD043488 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI MYATT, LESLIE · 2002 to 2023
$10.4M
Oregon BIRCWH: Scholars in Women's Health Research Across the LifespanK12AR084221 · NIAMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI LESLIE MYATT · 2023 to 2026
$2.2M
Identifying and modulating pathologic T cells that govern oral mucosal immune related adverse events from immune checkpoint blockadeR01DE033038 · NIDCR · OREGON HEALTH & SCIENCE UNIVERSITY · PI Rajan P. Kulkarni · 2024 to 2026
$2.1M
CSRD VA I01 CX002750NIAMS NIH HHS K12 AR084221NICHD NIH HHS K12 HD043488NIDCR NIH HHS R01 DE033038
6 · The paper itself

Abstract

In the era of precision medicine, mounting evidence suggests that the time of therapy administration, or chronotherapy, has a great impact on treatment outcomes. Chronotherapy involves planning treatment timing by considering circadian rhythms, which are 24 h oscillations in behavior and physiology driven by synchronized molecular clocks throughout the body. The value of chronotherapy in cancer treatment is currently under investigation, notably in the effects of treatment timing on efficacy and side effects. Immune checkpoint inhibitor (ICI) therapy is a promising cancer treatment. However, many patients still experience disease progression or need to stop the therapy early due to side effects. There is accumulating evidence that the time of day at which ICI therapy is administered can have a substantial effect on ICI efficacy. Thus, it is important to investigate the intersections of circadian rhythms, chronotherapy, and ICI efficacy. In this review, we provide a brief overview of circadian rhythms in the context of immunity and cancer. Additionally, we outline current applications of chronotherapy for cancer treatment. We synthesize the 29 studies conducted to date that examine the impact of time-of-day administration on the efficacy of ICI therapy, its associated side effects, and sex differences in both efficacy and side effects. We also discuss potential mechanisms underlying these observed results. Finally, we highlight the challenges in this area and future directions for research, including the potential for a chronotherapeutic personalized medicine approach that tailors the time of ICI administration to individual patients' circadian rhythms.

Indexed as

cancerchronotherapycircadian rhythmsimmune checkpoint inhibitorimmune-related adverse eventsimmunotherapyinfusion timingsex differencesside effectstime-of-day administration

Identifiers

PMID40075580
PMCPMC11899640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.